Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm study of abemaciclib and endocrine therapy with stereotactic
radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer
brain metastases.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute